AstraZeneca Filing Accepted in Europe and Japan for Lung Cancer
AstraZeneca’s regulatory filings for a TAGRISSO and ORPATHYS combination have been accepted in Europe and Japan for a form of non-small cell lung cancer. The…
AstraZeneca (LSE:AZN) said its filings for the TAGRISSO plus ORPATHYS regimen have been accepted in Europe and Japan for MET-driven, EGFR-mutated non-small cell lung cancer. The submissions move the combination through regulatory review, supported by Phase III data the company described as robust and clinically meaningful.
The acceptance is a step toward possible use of the treatment in additional settings, but it is not an approval. Regulators still need to decide whether to authorize the regimen and determine its label.
The filings concern patients whose cancers are driven by MET and carry EGFR mutations. AstraZeneca said its submissions rely on Phase III results in MET-driven non-small cell lung cancer, describing the data as clinically meaningful for patients.
That distinction matters for the company’s oncology strategy: the filing extends its effort to develop combinations around specific tumor drivers, rather than relying on a single treatment setting for TAGRISSO. The news does not yet establish how widely the combination could be used; regulatory decisions will determine the next step.
What comes next for the AstraZeneca filing acceptance?
The next milestones are regulatory outcomes and label details in Europe and Japan, alongside the previously filed US application. Those decisions will clarify the approved use of the combination if regulators authorize it.
Safety and uptake data will also help show how the treatment performs once information becomes available, while results from SAFFRON and other Phase III oncology trials could affect how AstraZeneca’s cancer portfolio develops. The company’s 2026 guidance assumes mid-to-high single-digit top-line growth and low-double-digit core EPS growth for the year.
The filing sits within a broader oncology portfolio. European regulators have approved Enhertu for early HER2-positive breast cancer, and pivotal Sone Ve gastric cancer trials have reported positive results. These developments form part of the company’s wider focus on prescription medicines and targeted cancer treatments.
For patients and clinicians, the immediate significance is that the combination has advanced to review in two regions, not that it is already available for this use. For investors, the outcome will depend on whether regulators accept the submitted evidence and what conditions appear in any eventual label.
AstraZeneca is a £213.4b pharmaceuticals group, and the filing adds another regulatory milestone to its oncology work. The company’s Phase III submissions now await decisions in Europe and Japan.
